The brave new era of human genetic testing

Hans Jürgen Bandelt, Yong Gang Yao, Martin B. Richards, Antonio Salas

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The commercialization of 'big science' is in full swing, leading to situations in which the ethical principles of academia are beginning to be compromised. This is exemplified by the profitable business of genetic ancestry testing. The goals of this sort of 'big science' are not necessarily in any way novel, however. In particular, large genotyping projects have a certain start-up time when their design is frozen in, so that the projects often lag behind the development of genetic knowledge. On the other hand, extremely provisional knowledge about potential disease markers is being rapidly turned into questionable 'tests', purporting to determine risk factors for complex disorders, by private companies that are eager to get their share of a profitable market of the future. The flow of money generated by such concerns looks likely to erode traditional research operations and small-scale projects, which risk becoming pebbles on the 'big science' landscape.

LanguageEnglish
Pages1246-1251
Number of pages6
JournalBioEssays
Volume30
Issue number11-12
Early online date20 Oct 2008
DOIs
Publication statusPublished - Nov 2008
Externally publishedYes

Fingerprint

Medical Genetics
Genetic Testing
Operations research
Testing
Operations Research
Industry

Cite this

Bandelt, H. J., Yao, Y. G., Richards, M. B., & Salas, A. (2008). The brave new era of human genetic testing. BioEssays, 30(11-12), 1246-1251. https://doi.org/10.1002/bies.20837
Bandelt, Hans Jürgen ; Yao, Yong Gang ; Richards, Martin B. ; Salas, Antonio. / The brave new era of human genetic testing. In: BioEssays. 2008 ; Vol. 30, No. 11-12. pp. 1246-1251.
@article{fba2b510d48c43bc932036221e386cb4,
title = "The brave new era of human genetic testing",
abstract = "The commercialization of 'big science' is in full swing, leading to situations in which the ethical principles of academia are beginning to be compromised. This is exemplified by the profitable business of genetic ancestry testing. The goals of this sort of 'big science' are not necessarily in any way novel, however. In particular, large genotyping projects have a certain start-up time when their design is frozen in, so that the projects often lag behind the development of genetic knowledge. On the other hand, extremely provisional knowledge about potential disease markers is being rapidly turned into questionable 'tests', purporting to determine risk factors for complex disorders, by private companies that are eager to get their share of a profitable market of the future. The flow of money generated by such concerns looks likely to erode traditional research operations and small-scale projects, which risk becoming pebbles on the 'big science' landscape.",
author = "Bandelt, {Hans J{\"u}rgen} and Yao, {Yong Gang} and Richards, {Martin B.} and Antonio Salas",
year = "2008",
month = "11",
doi = "10.1002/bies.20837",
language = "English",
volume = "30",
pages = "1246--1251",
journal = "BioEssays",
issn = "0265-9247",
publisher = "John Wiley and Sons Inc.",
number = "11-12",

}

Bandelt, HJ, Yao, YG, Richards, MB & Salas, A 2008, 'The brave new era of human genetic testing', BioEssays, vol. 30, no. 11-12, pp. 1246-1251. https://doi.org/10.1002/bies.20837

The brave new era of human genetic testing. / Bandelt, Hans Jürgen; Yao, Yong Gang; Richards, Martin B.; Salas, Antonio.

In: BioEssays, Vol. 30, No. 11-12, 11.2008, p. 1246-1251.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The brave new era of human genetic testing

AU - Bandelt, Hans Jürgen

AU - Yao, Yong Gang

AU - Richards, Martin B.

AU - Salas, Antonio

PY - 2008/11

Y1 - 2008/11

N2 - The commercialization of 'big science' is in full swing, leading to situations in which the ethical principles of academia are beginning to be compromised. This is exemplified by the profitable business of genetic ancestry testing. The goals of this sort of 'big science' are not necessarily in any way novel, however. In particular, large genotyping projects have a certain start-up time when their design is frozen in, so that the projects often lag behind the development of genetic knowledge. On the other hand, extremely provisional knowledge about potential disease markers is being rapidly turned into questionable 'tests', purporting to determine risk factors for complex disorders, by private companies that are eager to get their share of a profitable market of the future. The flow of money generated by such concerns looks likely to erode traditional research operations and small-scale projects, which risk becoming pebbles on the 'big science' landscape.

AB - The commercialization of 'big science' is in full swing, leading to situations in which the ethical principles of academia are beginning to be compromised. This is exemplified by the profitable business of genetic ancestry testing. The goals of this sort of 'big science' are not necessarily in any way novel, however. In particular, large genotyping projects have a certain start-up time when their design is frozen in, so that the projects often lag behind the development of genetic knowledge. On the other hand, extremely provisional knowledge about potential disease markers is being rapidly turned into questionable 'tests', purporting to determine risk factors for complex disorders, by private companies that are eager to get their share of a profitable market of the future. The flow of money generated by such concerns looks likely to erode traditional research operations and small-scale projects, which risk becoming pebbles on the 'big science' landscape.

UR - http://www.scopus.com/inward/record.url?scp=58149147497&partnerID=8YFLogxK

U2 - 10.1002/bies.20837

DO - 10.1002/bies.20837

M3 - Article

VL - 30

SP - 1246

EP - 1251

JO - BioEssays

T2 - BioEssays

JF - BioEssays

SN - 0265-9247

IS - 11-12

ER -